Menu Search
Equities

Catalyst Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
CN2:MUN

Catalyst Pharmaceuticals Inc

Actions
  • Price (EUR)20.52
  • Today's Change-0.03 / -0.15%
  • Shares traded60.00
  • 1 Year change-7.28%
  • Beta0.7342
Data delayed at least 15 minutes, as of Feb 12 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.

  • Revenue in USD (TTM)578.20m
  • Net income in USD217.56m
  • Incorporated2006
  • Employees181.00
  • Location
    Catalyst Pharmaceuticals Inc355 ALHAMBRA CIRCLE, SUITE 801CORAL GABLES 33134United StatesUSA
  • Phone+1 (305) 529-2522
  • Fax+1 (302) 636-5454
  • Websitehttps://catalystpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.